[Abstract Only] Randomized Trial: Overall Survival with Daratumumab, Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Commentary: Overall Survival With the Addition of Daratumumab to VMP in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma -The ASCO Post (free)